Use of Cannabinoids for Spasticity and Pain Management in MS

Hardeep Chohan, Ariele L. Greenfield, Vijayshree Yadav, Jennifer Graves

Research output: Contribution to journalReview articlepeer-review

9 Scopus citations


Several randomized trials have demonstrated potential benefit of cannabis derivatives in the symptomatic treatment of multiple sclerosis (MS) patients. These provide class 1 and 2 evidence for cannabinoid product use for spasticity and pain in these patients. The precise best ratio or doses are not yet clear. The safety and potential long-term effects of these products on cognitive function in people with MS have not been evaluated. Since short-term memory and processing speed can be significantly impaired in many people with MS, the concern of potential cognitive impairment related to cannabis products needs consideration in clinical care and should be addressed in longer, prospective studies.

Original languageEnglish (US)
Article number1
Pages (from-to)1-14
Number of pages14
JournalCurrent Treatment Options in Neurology
Issue number1
StatePublished - Jan 1 2016


  • Cannabidiol
  • Cannabinoids
  • Multiple sclerosis
  • Pain
  • Spasticity
  • Tetrahydrocannabinol

ASJC Scopus subject areas

  • Clinical Neurology


Dive into the research topics of 'Use of Cannabinoids for Spasticity and Pain Management in MS'. Together they form a unique fingerprint.

Cite this